Pierre Legault - 05 Aug 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, as Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
05 Aug 2022
Transactions value $
-$331,062
Form type
4
Filing time
09 Aug 2022, 16:05:04 UTC
Previous filing
03 Feb 2022
Next filing
05 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $96,300 +10,000 +31% $9.63 42,000 05 Aug 2022 Direct
transaction SNDX Common Stock Sale -$230,159 -10,000 -24% $23.02 32,000 05 Aug 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $125,020 +14,000 +44% $8.93 46,000 05 Aug 2022 Direct
transaction SNDX Common Stock Sale -$322,222 -14,000 -30% $23.02 32,000 05 Aug 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -10,000 -100% $0* 0 05 Aug 2022 Common Stock 10,000 $9.63 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -14,000 -100% $0* 0 05 Aug 2022 Common Stock 14,000 $8.93 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 39,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $23.00 to $23.12
F3 This option is fully vested.